Pirfenidone in patients with progressive fibrotic interstitial lung diseases other than idiopathic pulmonary fibrosis (RELIEF): a double-blind, randomised, placebo-controlled, phase 2b trial

Antje Prasse; Jürgen Behr

doi:https://doi.org/10.1016/s2213-2600(20)30554-3

doi.org/10.1016/s2213-2600(20)30554-3

Other

Pirfenidone in patients with progressive fibrotic interstitial lung diseases other than idiopathic pulmonary fibrosis (RELIEF): a double-blind, randomised, placebo-controlled, phase 2b trial

,

The Lancet Respiratory Medicine38.70

Volume: 9, Issue: 5, Pages: 476 - 486

Published: Mar 31, 2021

Paper Fields

Paper Details

Title

Pirfenidone in patients with progressive fibrotic interstitial lung diseases other than idiopathic pulmonary fibrosis (RELIEF): a double-blind, randomised, placebo-controlled, phase 2b trial

DOI

doi.org/10.1016/s2213-2600(20)30554-3

Published Date

Mar 31, 2021

Journal

The Lancet Respiratory Medicine

Volume

9

Issue

5

Pages

476 - 486

Notes

History